Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7%

Key Points

• Short interest in Pyxis Oncology fell by 14.7% in April to 2,269,065 shares, equal to about 4.0% of shares short and a short-interest ratio of 5.6 days based on average daily volume.
• Pyxis reported Q1 EPS of ($0.29), beating estimates by $0.06, and reported revenue of $11.04 million versus a $0.13 million consensus; the stock trades near $1.72 with a market cap of roughly $108.1 million.
• Analysts have an average rating of "Moderate Buy" with an average price target of $7.00, and institutional investors hold about 39.1% of the company's shares.

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) was the target of a large decrease in short interest during the month of April. As of April 15th, there was short interest totaling 2,269,065 shares, a decrease of 14.7% from the March 31st total of 2,660,931 shares. Based on an average daily volume of 402,636 shares, the short-interest ratio is currently 5.6 days. Currently, 4.0% of the shares of the stock are short sold.

Pyxis Oncology Trading Up 1.2%

Shares of NASDAQ:PYXS traded up $0.02 during trading on Friday, reaching $1.72. The company's stock had a trading volume of 102,324 shares, compared to its average volume of 607,646. Pyxis Oncology has a 12 month low of $0.97 and a 12 month high of $5.55. The firm's 50 day simple moving average is $1.55 and its two-hundred day simple moving average is $2.38. The stock has a market capitalization of $108.07 million, a PE ratio of -1.33 and a beta of 1.41.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. The business had revenue of $11.04 million during the quarter, compared to the consensus estimate of $0.13 million. Research analysts anticipate that Pyxis Oncology will post -1.24 EPS for the current fiscal year.

Institutional Trading of Pyxis Oncology

Several institutional investors have recently added to or reduced their stakes in PYXS. Maia Wealth LLC bought a new stake in Pyxis Oncology in the fourth quarter worth about $25,000. Engineers Gate Manager LP bought a new stake in Pyxis Oncology in the fourth quarter worth about $26,000. Fox Run Management L.L.C. bought a new stake in Pyxis Oncology in the fourth quarter worth about $26,000. Avanza Fonder AB bought a new stake in Pyxis Oncology in the fourth quarter worth about $31,000. Finally, XTX Topco Ltd bought a new stake in Pyxis Oncology in the second quarter worth about $40,000. Institutional investors own 39.07% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. HC Wainwright reissued a "buy" rating and set a $7.00 price objective on shares of Pyxis Oncology in a report on Tuesday, March 24th. Weiss Ratings reissued a "sell (d-)" rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Stifel Nicolaus dropped their price objective on shares of Pyxis Oncology from $9.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, March 24th. Finally, Wall Street Zen raised shares of Pyxis Oncology from a "sell" rating to a "hold" rating in a report on Monday, April 13th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $7.00.

About Pyxis Oncology

Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.